Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
Text
Soliris® (eculizumab) – Expanded indication
February 28, 2025 - The FDA approved AstraZeneca’s Soliris (eculizumab), for the treatment of generalized myasthenia gravis (gMG) in adult and pediatric patients 6 years of age and older who are anti-acetylcholine receptor (AChR) antibody positive.
